

Datasheet: MCA87PECY5.5

Description:	MOUSE ANTI HUMAN CD45:RPE-Cy5.5
Specificity:	CD45
Other names:	LCA
Format:	RPE-CY5.5
Product Type:	Monoclonal Antibody
Clone:	F10-89-4
Isotype:	IgG2a
Quantity:	100 TESTS

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	•			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human			
Product Form	Purified IgG conjugate	ed to R. Phycoerythrin	-Cy5.5 (RPE-Cy5.5) - lyc	philized
Reconstitution	Reconstitute with 1.0 r	ml distilled water		
		J	as the protein may appea t the vial is gently mixed a	
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)	
	RPE-Cy5.5 488nm laser	496	695	
Preparation	Purified IgG prepared supernatant	by affinity chromatog	raphy on Protein A from t	issue cu
Buffer Solution	Phosphate buffered sa	aline		
Preservative	0.09% Sodium Azide			

Stabilisers	1% Bovine Serum Albumin
	5% Sucrose
Immunogen	Human T lymphocytes.
External Database Links	UniProt: P08575 Related reagents
	Entrez Gene:
	5788 PTPRC Related reagents
Synonyms	CD45
RRID	AB_10844351
Fusion Partners	Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS-1 myeloma cell line.
Specificity	Mouse anti Human CD45 antibody, clone F10-89-4 recognizes the human CD45 cell surface antigen, also known as leucocyte common antigen (LCA). CD45 is a complex molecule existing in a number of isoforms.
	Antibodies recognizing a common epitope on all of these isoforms are termed CD45 whilst those recognizing only individual isoforms are termed CD45RA or CD45RO etc.
	Mouse anti Human CD45 antibody, clone F10-89-4 reacts with all forms of CD45 expressed by all haematopoietic cells, except erythrocytes, having a higher level of expression on lymphocytes than on granulocytes. It is routinely tested in flow cytometry on human peripheral blood leucocytes.
	Mouse anti Human CD45 antibody, clone F10-89-4, has been validated for use on the Genesis Cell Isolation System with the CelSelect Slide TM technology.
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells or 100ul whole blood
References	 Quenby, S <i>et al.</i> (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. <u>Human Reprod. 14(9):2386-2391.</u> Hauser, P.V. <i>et al.</i> (2010) Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. <u>Am J Pathol. 177: 2011-21.</u> Mallam, E. <i>et al.</i> (2010) Characterization of <i>in vitro</i> expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. <u>Mult Scler. 16: 909-18.</u> Marrinucci, D. <i>et al.</i> (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. <u>J Oncol. 2010: 861341.</u> Paul, G. <i>et al.</i> (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. <u>PLoS One. 7: e35577.</u> De Schauwer, C. <i>et al.</i> (2012) In search for cross-reactivity to immunophenotype equine

mesenchymal stromal cells by multicolor flow cytometry. Cytometry A. 81 (4): 312-23.

- 7. Kazane, S.A. *et al.* (2012) Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. Proc Natl Acad Sci U S A. 109: 3731-6.
- 8. Spaas, J.H. *et al.* (2013) Culture and characterisation of equine peripheral blood mesenchymal stromal cells. <u>Vet J. 195 (1): 107-13.</u>
- 9. Sadarangani, A. *et al.* (2015) GLI2 inhibition abrogates human leukemia stem cell dormancy. <u>J Transl Med. 13: 98.</u>
- 10. Gunawardene, P. *et al.* (2015) Association Between Circulating Osteogenic Progenitor Cells and Disability and Frailty in Older Persons: The Nepean Osteoporosis and Frailty Study. <u>J Gerontol A Biol Sci Med Sci. pii: glv190.</u>
- 11. Mohamed Suhaimi, N.A. *et al.* (2015) Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. <u>Mol Oncol. 9 (4):</u> 850-60.
- 12. Ruiz, C. *et al.* (2015) Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol. 12 (1): 016008.
- 13. Gogoi P *et al.* (2016) Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS One. 11 (1): e0147400.
- 14. Gomiero, C. *et al.* (2016) Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. <u>Vet Res Commun. 40 (1): 39-48.</u>
- 15. Bianchessi, M. *et al.* (2016) Effect of Fibroblast Growth Factor 2 on Equine Synovial Fluid Chondroprogenitor Expansion and Chondrogenesis. <u>Stem Cells Int. 2016</u>: 9364974.
- 16. Branly, T. *et al.* (2017) Characterization and use of Equine Bone Marrow Mesenchymal Stem Cells in Equine Cartilage Engineering. Study of their Hyaline Cartilage Forming Potential when Cultured under Hypoxia within a Biomaterial in the Presence of BMP-2 and TGF-β1. Stem Cell Rev Rep. 13 (5): 611-30.
- 17. GarikipatiV, N.S. *et al.* (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart. PLoS One. 13 (2): e0192244.
- 18. Shishido, S.N. *et al.* (2019) Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <u>J Transl Med. 17 (1): 294.</u>
- 19. Welter, L. *et al.* (2020) Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <u>Cold Spring Harb Mol Case Stud. 6 (6): a005819</u>.
- 20. Ndacayisaba, L.J. *et al.* (2022) Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones <u>Curr Oncol. 29 (5): 2954-72.</u>
- 21. Shishido, S.N. *et al.* (2022) Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma. <u>Cancers (Basel)</u>. 14 (12): 3007.
- 22. Chai, S. *et al.* (2022) Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol. 6 (1): 41.
- 23. Zhu, J. *et al.* (2022) Sequential Method for Analysis of CTCs and Exosomes from the Same Sample of Patient Blood. <u>ACS Omega. 7 (42): 37581-88.</u>
- 24. Setayesh, S.M. *et al.* (2022) Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. NPJ Breast Cancer. 8 (1): 112.
- 25. Ndacayisaba, L.J. *et al.* (2022) Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. <u>Int J Mol Sci. 23 (21): 13427.</u> 26. Qi, E. *et al.* (2023) Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection. <u>EBioMedicine. 90: 104519.</u>

27. Seo, J. *et al.* (2023) Plasticity of circulating tumor cells in small cell lung cancer. <u>Sci</u> Rep. 13 (1): 11775.

28. Setayesh, S.M. *et al.* (2023) Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. <u>NPJ Precis Oncol. 7 (1): 95.</u>

29. Welter, L. *et al.* (2023) Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. <u>Cancers (Basel)</u>. 15 (15): 3949.

30. Shishido, S.N. *et al.* (2024) Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. NPJ Precis Oncol. 8 (1): 36.

Storage Prior to reconstitution store at +4°C.

After reconstitution store at +4°C.

DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we

recommend microcentrifugation before use

Guarantee	12 months from date of despatch
Acknowledgements	Cy® and CyDye® are registered trademarks of GE Healthcare
Health And Safety Information	Material Safety Datasheet documentation #20487 available at: https://www.bio-rad-antibodies.com/SDS/MCA87PECY5.5 20487
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

North & South Tel: +1 800 265 7376

America

Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M419747:230616'

Printed on 17 Apr 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint